Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Uchida

Showing results (391-400 of 461) with videos related to

Pageof 47
Sort By:
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 22, 2024
Optimizing the identification of long-interval intracortical inhibition from the dorsolateral prefrontal cortexMayuko Takano, Masataka Wada, Shinichiro Nakajima, et al.
Brain Tumor Pathology|June 11, 2013
Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostainingHirofumi Hirano, Hajime Yonezawa, Shunji Yunoue, et al.
International Psychogeriatrics|May 17, 2014
Japanese versions of the executive interview (J-EXIT25) and the executive clock drawing task (J-CLOX) for older peopleTeruyuki Matsuoka, Yuka Kato, Shogo Taniguchi, et al.
Neuro-Oncology Advances|August 1, 2022
Prognostic impact of <i>PDGFRA</i> gain/amplification and <i>MGMT</i> promoter methylation status in patients with <i>IDH</i> wild-type glioblastomaNayuta Higa, Toshiaki Akahane, Seiya Yokoyama, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumTony Kaku, Shogyoku Bun, Koki Takahashi, et al.
Frontiers in Psychiatry|April 30, 2024
Comparison of changes in stress coping strategies between cognitive behavioral therapy and pharmacotherapySakae Ihara, Nariko Katayama, Waka Nogami, et al.
Schizophrenia Bulletin|July 30, 2015
Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical TrialShinichiro Nakajima, Hiroyuki Uchida, Robert R Bies, et al.
The Journal of Clinical Psychiatry|September 1, 2017
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's DiseaseSuzanne Reeves, Julie Bertrand, Emma McLachlan, et al.
Schizophrenia Bulletin|February 1, 2012
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE dataHitoshi Sakurai, Robert R Bies, Scott T Stroup, et al.
Neuro-Oncology Advances|September 25, 2023
Alterations in <i>EGFR</i> and <i>PDGFRA</i> are associated with the localization of contrast-enhancing lesions in glioblastomaRyutaro Makino, Nayuta Higa, Toshiaki Akahane, et al.
Pageof 47

Showing results (391-400 of 461) with videos related to

Sort By:
Pageof 47
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 22, 2024
Optimizing the identification of long-interval intracortical inhibition from the dorsolateral prefrontal cortexMayuko Takano, Masataka Wada, Shinichiro Nakajima, et al.
Brain Tumor Pathology|June 11, 2013
Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostainingHirofumi Hirano, Hajime Yonezawa, Shunji Yunoue, et al.
International Psychogeriatrics|May 17, 2014
Japanese versions of the executive interview (J-EXIT25) and the executive clock drawing task (J-CLOX) for older peopleTeruyuki Matsuoka, Yuka Kato, Shogo Taniguchi, et al.
Neuro-Oncology Advances|August 1, 2022
Prognostic impact of <i>PDGFRA</i> gain/amplification and <i>MGMT</i> promoter methylation status in patients with <i>IDH</i> wild-type glioblastomaNayuta Higa, Toshiaki Akahane, Seiya Yokoyama, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumTony Kaku, Shogyoku Bun, Koki Takahashi, et al.
Frontiers in Psychiatry|April 30, 2024
Comparison of changes in stress coping strategies between cognitive behavioral therapy and pharmacotherapySakae Ihara, Nariko Katayama, Waka Nogami, et al.
Schizophrenia Bulletin|July 30, 2015
Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical TrialShinichiro Nakajima, Hiroyuki Uchida, Robert R Bies, et al.
The Journal of Clinical Psychiatry|September 1, 2017
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's DiseaseSuzanne Reeves, Julie Bertrand, Emma McLachlan, et al.
Schizophrenia Bulletin|February 1, 2012
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE dataHitoshi Sakurai, Robert R Bies, Scott T Stroup, et al.
Neuro-Oncology Advances|September 25, 2023
Alterations in <i>EGFR</i> and <i>PDGFRA</i> are associated with the localization of contrast-enhancing lesions in glioblastomaRyutaro Makino, Nayuta Higa, Toshiaki Akahane, et al.
Pageof 47